Jason A. Sprowl PhD

Jason Sprowl

Jason A. Sprowl
PhD

Assistant Professor

Department of Pharmaceutical Sciences

School of Pharmacy


Specialty/Research Focus

Cancer Chemotherapy; Drug Delivery; Drug Targeting; Drug Transport; Drug Utilization Research; Drug-Drug Interactions; Pharmacodynamic; Pharmacogenetics; Pharmacogenomics; Pharmacogenomics; Pharmacokinetic; Pharmacokinetics; PK/PD; Toxicology; Translational Research

Contact Information
372 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4849
Fax: 716-829-6569
jasonspr@buffalo.edu



Professional Summary:

Our research program primarily conducts translational studies that aim to identify and characterize regulators of drug disposition which contributes to the variability of drug toxicity or efficacy in cancer patients. We currently focus on the role of transporter proteins in regulating drug or nutrient uptake and accumulation.

Education and Training:

  • Postdoctoral Fellow, Pharmaceutical Sciences, St. Jude Children‘s Research hospital (2014)
  • PhD, Biomolecular Sciences, Laurentian University (2010)
  • BS, Biochemistry, Laurentian University (2004)

Employment:

  • Assistant Professor, Pharmaceutical Sciences, University at Buffalo (2018-present)
  • Assistant Professor, Pharmaceutical, Social and Administrative Sciences, D'Youville College (2014–2018)

Awards and Honors:

  • CTSI KL2 Scholar (2020)
  • AACP New Investigator Award (2019)
  • Faculty Member of the Year - D‘Youville College, School of Pharmacy, Department of Pharmaceutical, Social and Administrative Sciences (2018)
  • Carl Jackson Postdoctoral Excellence Award (2014)
  • David Goldstein Trainee Award (2012)

Research Expertise:

  • Membrane Transporters: Role of transporters in regulating pharmacokinetics and pharmacodynamics of therapeutics. Membrane transporters as regulators of drug toxicity.
  • Pharmacogenomics: Identification and characterization of proteins with genetic variation that can impact treatment outcome

Grants and Sponsored Research:

  • July 2020–June 2022
    Regulation of Cisplatin-induced Ototoxicity by the Monocarboxylate Transporter MCT6
    Buffalo Translational Consortium
    Role: Principal Investigator
    $489,208
  • May 2020–May 2022
    Sustained Release of Luzindole
    Buffalo Blue Sky Program
    Role: Co-Investigator
    $10,000
  • June 2020–January 2022
    SGLT Activity as a Mediator of Tyrosine Kinase Inhibitor Treatment Outcome
    School of Pharmacy and Pharmaceutical Sciences Seed Support Program
    Role: Principal Investigator
    $7,500
  • January 2019–January 2020
    Regulation of SGLT1 Function by Tyrosine Kinase Inhibitors
    AACP
    Role: Principal Investigator
    $9,864
  • October 2018–January 2020
    Kinase-mediated regulation of OATP Transporters
    School of Pharmacy and Pharmaceutical Sciences Seed Support Program
    Role: Principal Investigator
    $5,000

Patents:

  • TNF gene expression to assess response to taxanes or anthracyclines TNF-related gene expression used as a biomarker to measure response to taxanes or anthracycles (2014)

Journal Articles:

See all (14 more)

Professional Memberships:

  • American Society for Pharmacology and Experimental Therapeutics (ASPET) (2018–present)
  • Rho Chi Society (2018–present)
  • American Association of Colleges of Pharmacy (AACP) (2014–present)
  • American Society For Clinical Pharmacology and Therapeutics (ASCPT) (2011–2015)
  • American Association For Cancer Research (AACR) (2008–2015)

Presentations:

  • "Influence of tyrosine kinase inhibitors and tyrosine phosphorylation sites on SGLT1 function" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
  • "Regulation of OATP1B1 activity by tyrosine kinase-mediated phosphorylation" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
  • "Managing Drug Efficacy and Safety when Transporters get Perturbed" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
  • "Influence of kinase inhibitors on membrane transporters – risk of drug-drug interactions and adverse events" Roswell Park Comprehensive Cancer Center Lung Translational Research Group Meeting, Roswell Park Comprehensive Cancer Center Lung Translational Research Group (2021)
  • "Membrane Transporter Community Network and Community Experience" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
  • "Proteomics-informed prediction of transporter-enzyme interplay in drug disposition" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2021)
  • "Genomics and Toxicology – Genetic Predisposition to Drug Toxicity”" North American Congress of Clinical Toxicology Annual Meeting, North American Congress of Clinical Toxicology (2020)
  • "Regulation of SGLT1 Function by Tyrosine Kinase Inhibitors" AACP Annual Meeting, AACP (2020)
  • "Role of transporters and S100A8/A9 in paclitaxel-induced peripheral neuropathy" Experimental Biology, ASPET (2020)
  • "Phosphorylation and function of OATP1B1 with tyrosine kinase inhibitors" Experimental Biology, ASPET (2020)
  • "Therapeutic Impact and Detection of Membrane Transporter Polymorphisms" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2020)
  • "Tyrosine Kinase Mediated Regulation of OATP1B1" 4th Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University (2019)
  • "Characterization of OATP1B1 and OATP1B3 inhibition by Nilotinib" Experimental Biology, ASPET (2019)
  • "Genetic and Pharmacological Inhibition of OCT2 protects rats against oxaliplatin-induced peripheral neuropathy" Experimental Biology 2019, ASPET (2019)
  • "Changes in Expression and Activity of Transporters: Do They Impact Pharmacokinetics and Toxicity of Drugs" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2018)
  • "Targeting transporters to ameliorate chemotherapy-induced peripheral neuropathy" EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, EORTC-NCI-AACR (2018)
  • "Genetic and pharmacological inhibition of OCT2 protects Rattus Norvegicus from Oxaliplatin-induced peripheral neuropathy" 3rd Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University (2018)
  • "Targeting OATP1B2 to ameliorate paclitaxel-induced chronic peripheral neuropathy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2018)
  • "Influence of Nilotinib and different Tyrosine Kinases on OATP1B1 Function" 2nd Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University, Pharmaceutical Sciences (2017)
  • "OATP1B2-deficiency protects against paclitaxel-induced neuropathy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2016)
  • "Identification of OAT1/OAT3 as contributors to cisplatin nephrotoxicity" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
  • "Tyrosine phosphorylation is essential for OCT2 function and a target of inhibition by TKIs" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
  • "Organic cation transporters mediate cisplatin and oxaliplatin side effects" International Conference of Anticancer Research, Anticancer Research (2014)
  • "Amelioration of oxaliplatin neurotoxicity by dasatinib" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
  • "Conjunctive therapy of cisplatin with OCT inhibitors: influence on antitumor efficacy and systemic clearance" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
  • "Identification of tyrosine kinase inhibitors as modulators of OCT2 function" EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, EORTC-NCI-AACR (2012)
  • "Association of ABCC2 polymorphisms with cisplatin disposition and efficacy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Contribution of p53 signaling to cisplatin nephrotoxicity in Oct1/Oct2-deficient mice" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Oxaliplatin-induced peripheral neurotoxicity is dependent on OCT2-mediated transport" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Role of the 1C aldo-keto reductases in resistance to doxorubicin in MCF-7 breast cancer cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2010)
  • "Resistance to TNFα in MCF-7 Cells during the acquisition of taxane resistance" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2009)
  • "Clustering of anthracycline-containing lysosomes in drug-resistant MCF-7 cells in response to tesmilifene" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
  • "Role of promoter methylation in the induction of ABCB1 gene expression in anthracycline-resistant and paclitaxel-resistant breast tumor cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
See all (23 more)

Service Activities:

  • ASCPT Membrane Transporter Community; Chair (2021–present)
  • Curricular Fall Planning Sub-Committee; Member (2020)
  • ASCPT Membrane Transporter Community; Vice-Chair (2020–2021)
  • ASCPT Pharmacogenomic Community; Member (2019–2020)
  • Outcomes and Assessment Committee; Vice-Chair (2019–present)
  • Outcomes and Assessment Committee; Member (2018–2019)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

372 Pharmacy Building
Buffalo, NY 14214-8033
Phone: (716) 645-4849
Fax: 716-829-6569
jasonspr@buffalo.edu